Research Analysts Issue Forecasts for Kamada Ltd.’s FY2018 Earnings (KMDA)
Kamada Ltd. (NASDAQ:KMDA) – Jefferies Group reduced their FY2018 earnings per share estimates for Kamada in a research note issued on Friday. Jefferies Group analyst R. Denhoy now expects that the biotechnology company will post earnings of $0.19 per share for the year, down from their prior estimate of $0.20. Jefferies Group currently has a “Buy” rating and a $7.00 target price on the stock. Jefferies Group also issued estimates for Kamada’s FY2019 earnings at $0.39 EPS and FY2020 earnings at $0.64 EPS.
Kamada (NASDAQ:KMDA) last released its quarterly earnings results on Tuesday, August 1st. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.01. Kamada had a negative net margin of 2.24% and a negative return on equity of 2.94%. The firm had revenue of $32.55 million for the quarter, compared to analysts’ expectations of $33.30 million. During the same quarter last year, the company earned ($0.04) EPS. The firm’s revenue for the quarter was up 70.7% compared to the same quarter last year.
A number of other research firms have also recently commented on KMDA. Zacks Investment Research upgraded Kamada from a “sell” rating to a “hold” rating in a report on Tuesday, August 15th. TheStreet cut Kamada from a “c-” rating to a “d+” rating in a report on Tuesday, August 1st.
Kamada (KMDA) traded up 1.16% during midday trading on Monday, reaching $4.35. 89,702 shares of the company were exchanged. The company’s market capitalization is $162.69 million. Kamada has a 52-week low of $3.75 and a 52-week high of $8.61. The company has a 50 day moving average of $4.95 and a 200-day moving average of $6.49.
A number of institutional investors have recently bought and sold shares of KMDA. Vanguard Group Inc. boosted its position in Kamada by 6.5% in the second quarter. Vanguard Group Inc. now owns 468,390 shares of the biotechnology company’s stock worth $2,810,000 after buying an additional 28,382 shares during the last quarter. Nexthera Capital LP bought a new stake in shares of Kamada during the second quarter valued at about $1,805,000. Renaissance Technologies LLC increased its stake in shares of Kamada by 16.7% in the first quarter. Renaissance Technologies LLC now owns 264,800 shares of the biotechnology company’s stock valued at $1,801,000 after buying an additional 37,800 shares during the period. Acadian Asset Management LLC bought a new stake in shares of Kamada during the first quarter valued at about $575,000. Finally, Norges Bank bought a new stake in shares of Kamada during the fourth quarter valued at about $377,000. Institutional investors and hedge funds own 7.15% of the company’s stock.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.